Europe’s and the UK’s healthtech sectors are gaining exceptional momentum in 2025. According to PitchBook’s Q1 report, healthtech VC funding surged 30.4%, reaching $3.5 billion across 185 deals, driven by B2B AI tools and consumer-facing platforms.
Simultaneously, the broader European startup ecosystem is preparing for scale. Reuters reports that the European Commission is rolling out a €10 billion “Scaleup Europe Fund”, aimed at addressing gaps in late-stage financing and levelling the playing field with the U.S. and China.
Together, these developments have created fertile ground for standout scaleups. Skyrocketing investment activity and structural support via large-scale funds are propelling a new generation of healthtech innovators toward growth and market leadership.
Here are seven scaleups that are poised to redefine healthcare in Europe and the UK.
MoonLake Immunotherapeutics (Switzerland)
Founder/s: Jorge Santos daa Silva
Founded year: 2021
Valuation: $3B
Swiss-based clinical-stage biopharmaceutical company MoonLake Immunotherapeutics leverages its innovative Nanobody technology to develop advanced treatments for inflammatory conditions. Its lead candidate, sonelokimab, targets IL-17A/F-driven diseases and is currently in Phase 3 trials for psoriatic arthritis and hidradenitis suppurativa, areas with significant unmet medical needs. The company is advancing a broader pipeline in dermatology and rheumatology, positioning itself to deliver next-level therapies that elevate patient care.
In April this year, MoonLake secured up to $500 million in non‑dilutive financing from Hercules Capital, including an immediate $75 million draw at closing, with additional tranches tied to pre-set milestone achievements. This facility bolsters the company’s existing cash position of $448 million. This will help advance its lead Nanobody candidate, sonelokimab, through late-stage trials and its anticipated 2027 launch.
Isomorphic Labs (UK)
Founder/s: Demis Hassabis
Founded year: 2021
Valuation: $2.4B
Being an Alphabet company focused on drug discovery, Isomorphic Labs uses machine learning to reimagine the entire drug development process. They aim to accelerate the discovery of new medicines by building powerful predictive and generative models leveraging AI and Google Cloud infrastructure.
Earlier this year, the company landed $600 million in its first external funding round. The round was led by Thrive Capital, with participation from GV, and followed by additional capital from Alphabet. The funding will enable the company to enhance its AI drug design engine and advance its drug pipeline toward clinical trials.
Anbio Biotechnology (Germany)
Founder/s: Michael Lau, Suki Song, Chris Tian
Founded year: 2021
Valuation: $1.9B
A German-based medical device company specialising in in vitro diagnostics (IVD), Anbio Biotechnology, aims to revolutionise diagnostics by making solutions more personalised, decentralised, rapid, accessible, and affordable. The company leverages strong R&D, manufacturing, and global distribution capabilities to deliver mature laboratory and point‑of‑care (POCT) diagnostic products across a broad spectrum of diseases, including infectious diseases, cancer, cardiovascular conditions, pharmacogenomics, hormones, inflammation, and drug abuse.
The company closed its initial public offering of 1,600,000 Class A ordinary shares for $5.00 each, raising a total of $8 million before expenses. The shares began trading on the Nasdaq Global Market under the ticker “NNNN” in February 2025.
Neko Health (Sweden)
Founder/s: Hjalmar Nilsonne, Daniel Ek
Founded year: 2021
Valuation: $1.8B
Swedish company Neko Health offers a full-body scanning system designed for broad and non-invasive health data collection. By leveraging over seventy sensors to collect fifty million data points, the company aims to provide quicker, more convenient, and affordable health assessments. The unique, non-invasive Neko Health Scan costs £299 and maps millions of health data points on the body, both inside and out, in just a few minutes. Immediately following the scan, members receive full results as part of a doctor-led consultation. The whole experience is complete in just under an hour.
Neko Health secured $260 million in Series B funding in January this year. The round was led by Lightspeed Venture Partners, with participation from General Catalyst, O.G. Venture Partners, Rosello, Lakestar, and Atomico.
Pharvaris (Netherlands)
Founder/s: Berndt Modig, Anne Lesage, Hans Schikan, Jochen Knolle, Luc Dochez
Founded year: 2015
Valuation: $1B
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all subtypes of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.
Last month, Pharvaris closed an oversubscribed $80 million Series C funding round. Viking Global Investors and General Atlantic co-led the financing, with participation by Cormorant Asset Management. Current investors Foresite Capital, Bain Capital Life Sciences, venBio Partners, and Venrock Healthcare Capital Partners also participated in the round.
Leyden Labs (Netherlands)
Founder/s: Jaap Goudsmit, Koenraad Wiedhaup, Ronald Brus
Founded year: 2020
Valuation: $700M
Amsterdam-headquartered Leyden Labs utilises its platform to target commonalities of viral families to protect against many viruses simultaneously, as opposed to vaccines that typically protect against a specific virus variant. The company’s platform is built on two concepts: broad protection against known viruses, new variants and newly emerging viruses. The company is advancing a novel class of broadly protective nasal sprays, including its PanFlu candidate containing the monoclonal antibody CR9114, which is currently in development for influenza prophylaxis.
The Dutch startup secured $70 million in funding in January this year. The investment was co-led by ClavystBio, a life sciences venture investor established by Temasek, and Polaris Partners, with participation by Qiming Venture Partners and existing investors. The company’s syndicate of VC investors now includes GV (formerly Google Ventures), Casdin Capital, F-Prime Capital, ClavystBio, Qiming Venture Partners, Invus, Byers Capital / Brook Byers, Bluebird Ventures, and Softbank Vision Fund 2.
Oculis (Switzerland)
Founder/s: Einar Stefánsson, Thorsteinn Loftsson
Founded year: 2017
Valuation: $681M
Yet another Swiss clinical-stage biopharmaceutical company, Oculis, is focused on developing novel topical treatments for ophthalmic diseases affecting both the front and back of the eye. The company primarily serves patients suffering from conditions such as diabetic macular oedema (DME) and post-cataract inflammation. Operating in the biopharmaceutical market, it leverages its proprietary SNP technology to create eye drop formulations that offer a non-invasive alternative to current treatments, which often involve intraocular injections or implants.
In February, Oculis announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, CHF 0.01 nominal value per share, for $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses.
Source link
